abs34.txt	in	its	landmark	paper	about	standards	and	guidelines	for	the	interpretation	ofsequence	variants		american	college	of	medical	genetics	genomics	(acmg)	association	molecular	pathology	(amp)	did	not	address	how	to	use	tumordata	when	assessing	pathogenicity	germline	clinical	genomeresource	(clingen)	established	a	multidisciplinary	working	group	thegermline/somatic	variant	subcommittee	(gsvs)	with	this	focus	gsvsimplemented	survey	determine	current	practices	integrating	somatic	datawhen	classifying	cancer	predisposition	genes	gsvs	thenreviewed	analyzed	available	resources	relevant	data	performedintegrative	curation	exercises	committee	determined	thatsomatic	hotspots	could	be	systematically	integrated	into	moderate	evidence	ofpathogenicity	(pm1)	tumor	rna	sequencing	showing	altered	splicing	may	beconsidered	as	strong	support	(pvs1)	andtumor	phenotypic	features	such	mutational	signatures	considered	supportingevidence	(pp4)	however	at	present	focalloss	heterozygosity	mutations	occurring	on	alternative	allele	are	notrecommended	instead	incorporation	typeof	should	take	place	under	advisement	centertumor-normal	boards
